We’ve recently updated our valuation analysis.

Corcept Therapeutics Valuation

Is CORT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CORT?

Other financial metrics that can be useful for relative valuation.

CORT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.8x
Enterprise Value/EBITDA17.9x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does CORT's PE Ratio compare to its peers?

The above table shows the PE ratio for CORT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average46x
PBH Prestige Consumer Healthcare
15.2x5.2%US$3.2b
BHC Bausch Health Companies
11.3x38.9%US$2.9b
PCRX Pacira BioSciences
103.8x30.9%US$2.2b
SUPN Supernus Pharmaceuticals
53.8x41.0%US$2.0b
CORT Corcept Therapeutics
23x29.1%US$2.7b

Price-To-Earnings vs Peers: CORT is good value based on its Price-To-Earnings Ratio (23x) compared to the peer average (46x).


Price to Earnings Ratio vs Industry

How does CORT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.5%
n/an/an/a

Price-To-Earnings vs Industry: CORT is expensive based on its Price-To-Earnings Ratio (23x) compared to the US Pharmaceuticals industry average (17.2x)


Price to Earnings Ratio vs Fair Ratio

What is CORT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CORT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23x
Fair PE Ratio21.1x

Price-To-Earnings vs Fair Ratio: CORT is expensive based on its Price-To-Earnings Ratio (23x) compared to the estimated Fair Price-To-Earnings Ratio (21.1x).


Share Price vs Fair Value

What is the Fair Price of CORT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CORT ($24.98) is trading below our estimate of fair value ($59.5)

Significantly Below Fair Value: CORT is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CORT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.98
US$32.17
+28.8%
25.2%US$45.00US$18.00n/a6
Nov ’23US$29.96
US$32.50
+8.5%
24.5%US$45.00US$18.00n/a6
Oct ’23US$25.64
US$32.50
+26.8%
24.5%US$45.00US$18.00n/a6
Sep ’23US$25.98
US$32.50
+25.1%
24.5%US$45.00US$18.00n/a6
Aug ’23US$27.33
US$29.83
+9.2%
22.2%US$35.00US$16.00n/a6
Jul ’23US$25.44
US$27.50
+8.1%
24.9%US$35.00US$16.00n/a6
Jun ’23US$20.74
US$26.83
+29.4%
23.7%US$35.00US$16.00n/a6
May ’23US$21.51
US$27.17
+26.3%
22.4%US$35.00US$16.00n/a6
Apr ’23US$23.65
US$27.17
+14.9%
22.4%US$35.00US$16.00n/a6
Mar ’23US$23.14
US$27.17
+17.4%
22.4%US$35.00US$16.00n/a6
Feb ’23US$18.81
US$26.40
+40.4%
25.2%US$35.00US$16.00n/a5
Jan ’23US$19.80
US$25.50
+28.8%
28.1%US$35.00US$16.00n/a4
Dec ’22US$21.16
US$24.75
+17.0%
30.8%US$35.00US$16.00US$24.944
Nov ’22US$18.21
US$25.25
+38.7%
28.9%US$35.00US$16.00US$29.964
Oct ’22US$19.84
US$25.25
+27.3%
28.9%US$35.00US$16.00US$25.644
Sep ’22US$21.65
US$25.25
+16.6%
28.9%US$35.00US$16.00US$25.984
Aug ’22US$20.77
US$25.25
+21.6%
28.9%US$35.00US$16.00US$27.334
Jul ’22US$22.53
US$25.75
+14.3%
27.4%US$35.00US$16.00US$25.444
Jun ’22US$21.54
US$26.50
+23.0%
28.3%US$35.00US$16.00US$20.744
May ’22US$22.79
US$27.00
+18.5%
27.1%US$35.00US$16.00US$21.514
Apr ’22US$24.43
US$27.00
+10.5%
27.1%US$35.00US$16.00US$23.654
Mar ’22US$25.46
US$27.00
+6.0%
27.1%US$35.00US$16.00US$23.144
Feb ’22US$29.29
US$25.75
-12.1%
24.0%US$32.00US$16.00US$18.814
Jan ’22US$26.16
US$25.00
-4.4%
25.6%US$32.00US$16.00US$19.804
Dec ’21US$22.99
US$25.00
+8.7%
25.6%US$32.00US$16.00US$21.164

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies